Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinic…
Biotechnology
US, San Diego [HQ]
C-Suite · BofD · VPs/SVPs
All the data Mirati Therapeutics, Inc. presents was sourced from the latest proxy filing.
The proxy statement is the most reliable resource when it comes to compensation breakdowns and other information where an audited is preferred.
Shows the total compensation per mentioned executive and board director.
Each datapoint refers the most recent appearance of the corresponding person.
C-Suite, BofD and VPs/SVPs Beta
The proxy statement is the most reliable resource when it comes to compensation breakdowns and other information where an audited is preferred.
C-Suite and VPs/SVPs
Board of Directors (BofD)
Proxy Sections
Our core belief is in providing transparent validation principles, so here are the document sections we used for retrieving the data over-time:Total Compensation ($)
Add Series
Each datapoint refers the most recent appearance of the corresponding person.